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Summary
Objectives: A few studies reported that some mutations in the cardiac myosin-binding protein
C (MyBPC) gene were associated with dilated phase of hypertrophic cardiomyopathy (D-HCM)
resembling dilated cardiomyopathy (DCM). We studied 5 unrelated cardiomyopathy probands
caused by an identical mutation in the MyBPC gene. The results of clinical and genetic investi-
gations in these patients are presented in this paper.
Methods: We analyzed MyBPC gene in DCM patients as well as patients with HCM.
Results: An R945fs/105 mutation, 2-base deletion at nucleotides 18,535 and 18,536, was identi-
ﬁed in 4 of the 176 HCM probands and in 1 of the 54 DCM probands. Genetic analysis in relatives
of those probands revealed another one member with this mutation. A total of 6 subjects had
R945fs/105 mutation. The mean age of these six patients at diagnosis was 61 years. At ini-
tial evaluation, three of them were diagnosed as having HCM with normal left ventricular (LV)
systolic function. The other two patients already had D-HCM. The remaining one patient was
diagnosed as having DCM because of reduced LV systolic function (ejection fraction = 31%) with-
out increased LV wall thickness.
LV systolic function were admitt
tachycardia. Finally, one patien
Conclusions: The patients with
from cardiovascular events thro
© 2010 Published by Elsevier Ire
∗ Corresponding author. Tel.: +81 (0) 88 880 2352; fax: +81 (0) 88 880 2
E-mail address: ydoi@kochi-u.ac.jp (Y.L. Doi).
0914-5087/$ — see front matter © 2010 Published by Elsevier Ireland Ltd
doi:10.1016/j.jjcc.2010.04.003During follow-up (7.6 years), all three patients with impaired
ed for treatment of heart failure and/or sustained ventricular
t with the diagnosis of D-HCM died of heart failure.
this mutation may develop LV systolic dysfunction and suffer
ugh mid-life and beyond.
land Ltd on behalf of Japanese College of Cardiology.
349.
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Table 1 Clinical characteristics of patients with an R945fs/105 mutation in the MyBPC gene at intial evaluation.
Patient No. Gender Age (years) at
initial
Age (years) at
diagnosis
Reason for
diagnosis
Rhythm Proven familial HCM NYHA class
H108 F 79 78 ECG abnormality SR − II
H180 M 59 59 Chest pain SR − I
H053-III-3 F 55 55 ECG abnormality SR + I
H053-III-4 M 50 48 Heart failure SR + III
H085 F 63 63 Heart failure SR + III
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MyBPC, cardiac myosin-binding protein C; HCM, hypertrophic ca
female; M, male; ECG, electrocardiography; SR, sinus rhythm; AF,
ntroduction
ypertrophic cardiomyopathy (HCM) is a primary myocar-
ial disorder with heterogeneous morphologic, functional,
nd clinical features [1—4]. Molecular genetic studies have
evealed that HCM is caused by mutations in more than 10
enes that encode sarcomere contractile proteins [5—9].
ardiac myosin-binding protein C (MyBPC) is one of these
arcomere proteins, and mutations in the MyBPC gene have
een reported to be associated with delayed expression of
ypertrophy and a relatively good prognosis [10—15].
On the other hand, we recently reported that patients
ith one mutation in the MyBPC gene evolved into dilated
hase of HCM (D-HCM) characterized by left ventricular (LV)
ystolic dysfunction and cavity dilatation, resembling the
orphologic features of dilated cardiomyopathy (DCM) [16].
his suggests that patients with MyBPC mutations may at
imes be diagnosed clinically as having DCM. Therefore, we
nalyzed the MyBPC gene in DCM patients as well as patients
ith HCM and had the opportunity to study 4 unrelated
CM families and 1 DCM proband living in Kochi Prefec-
ure, Japan, who were found to have an identical frameshift
utation in the MyBPC gene: a 2-base deletion of a cytosine
nd guanine at nucleotides 18,535 and 18,536 (R945fs/105).
he results of clinical and genetic investigations in these
atients are presented in this paper.
ethods
ubjects
he subjects were 176 probands with HCM and 54 probands
ith DCM. All probands were evaluated at the Kochi Medical
chool Hospital for conﬁrmation of diagnosis, risk assess-
ent, and symptom management between 1982 and 2007.
he diagnosis of HCM was based on echocardiographic
emonstration of an unexplained LV hypertrophy (LVH), i.e.,
aximum LV wall thickness (MLVWT) ≥15mm. The diag-
ostic criteria of DCM were: (1) a dilated left ventricle
LV end-diastolic diameter (LVEDD) >55mm)] with ejection
raction (EF) <50% and (2) exclusion of patients with acute
yocarditis, speciﬁc heart muscle disease, general systemic
isease, signiﬁcant coronary artery stenosis (deﬁned as
iameter narrowing of ≥50% in any major coronary arteries
r their branches), valvular disease, sensitivity/toxic reac-
ions, and history of excessive alcohol intake [17]. Relatives
g
(
c
o
ofailure AF − IV
yopathy; NYHA, New York Heart Association functional class; F,
l ﬁbrillation.
f probands were contacted by the probands themselves
nd visited our clinic of their own free will. Following the
dentiﬁcation of an R945fs/105 mutation, pedigree analy-
is, including both clinical evaluation and genotyping, was
erformed. Informed consent was given from all subjects in
ccordance with the guidelines of the Ethics Committee on
edical Research of Kochi Medical School.
linical evaluation
valuation of probands and relatives included medical
istory, clinical examination, 12-lead electrocardiography
ECG), M-mode, two-dimensional (2D) and Doppler echocar-
iography, and ambulatory 24-h Holter ECG analysis. The
everity and distribution of LVH were assessed in the
arasternal short axis plane at mitral valve and papilliary
uscle levels [18,19]. MLVWT was deﬁned as the greatest
hickness in any single segment. LVEDD and LV end-systolic
iameter (LVESD) were measured from M-mode and 2D
mages obtained from parasternal long-axis views, and frac-
ional shortening (FS = 100× (LVEDD− LVESD)/LVEDD) was
alculated. Global EF was determined from apical two- and
our-chamber views. LV outﬂow tract gradient was calcu-
ated from continuous-wave Doppler using the simpliﬁed
ernoulli equation.
D-HCM was deﬁned as LV systolic dysfunction of global EF
50% at study entry or during follow-up in the presence of
1) an unexplained LV hypertrophy (MLVWT ≥15mm), or (2)
revious documentation of unexplained LVH on echocardio-
raphy (MLVWT ≥15mm), or (3) proven familial HCM with
t least 1 relative who had an unequivocal diagnosis. Con-
omitant coronary artery disease was excluded by coronary
ngiography.
Phenotypically affected relatives were deﬁned by the fol-
owing criteria: (1) MLVWT ≥13mm, (2) presence of major
bnormalities on an ECG (i.e. Q wave ≥0.04 s in duration
r one-fourth of the ensuing R wave in depth in at least two
eads, signiﬁcant ST-T changes, and Romhilt-Estes score >4),
r (3) a combination of criteria 1 and 2.
Data regarding survival and clinical status of patients
ere collected during serial clinic visits. Evaluation of
he phenotype was completed before determination of the
enotype. Three modes of HCM-related death were deﬁned:
1) sudden and unexpected death (including resuscitated
ardiac arrest), in which collapse occurred in the absence
r <1 h from the onset of symptoms in patients who previ-
usly experienced a relatively stable or uneventful course;
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aFigure 1 Pedigree of families H053, H085, H108, H180, and
indicated.
(2) heart failure-related death, which was in the context of
progressive cardiac decompensation ≥1 year before death,
particularly if complicated by pulmonary edema or evolu-
tion to the end-stage phase; and (3) stroke-related death,
which occurred in patients who died as a result of embolic
stroke.Genetic analysis
Peripheral blood samples were taken at the time of clini-
cal evaluation, and they were frozen and stored at −20 ◦C.
T
I
w
G
m. The genotypic status and phenotypic status of subjects are
eoxyribonucleic acid (DNA) was extracted using a DNA
uriﬁcation kit from QIAGEN Inc. (no. 51104; Hilden, Ger-
any). In vitro ampliﬁcation of genomic DNA was performed
sing the polymerase chain reaction (PCR). Oligonucleotide
rimers were used to amplify exon 27 of the MyBPC gene.
nformation on primer sequences and PCR conditions is avail-
ble upon request. Sequencing was performed using a BigDye
erminator Cycle Sequencing Kit from Applied Biosystems
nc. (no. 4336774; Foster City, CA, USA). The sequences
ere analyzed on an Applied Biosystems PRISM 3100-Avant
enetic Analyzer in accordance with the manual of the
anufacturer. In patients in whom the mutation was iden-
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iﬁed, conﬁrmation was obtained by re-analysis with direct
equencing from a second blood sample.
To investigate if families carrying the identical muta-
ion were related, haplotype analysis was performed using
icrosatellite markers deﬁning the MyBPC gene locus.
arkers MyBPC3-CA, D11S1784, and D11S1326, ﬂanking the
yBPC gene, were used. To describe haplotype results, the
ength (base pairs) of allele was put in parentheses after
ach marker.
esults
enetic results
n R945fs/105 mutation, a frameshift mutation that causes
runcation of cardiac MyBPC protein, was identiﬁed in 4 of
he 176 HCM probands and in 1 of the 54 DCM probands.
enetic analysis in relatives of those probands revealed
nother one member with this mutation. A total of 6 sub-
ects, including 5 probands, had an R945fs/105 mutation in
he MyBPC gene (Fig. 1). This mutation was thought to be
isease-causing based on presence of the mutation in all
ffected individuals and absence of sequence variation in at
east 776 chromosomes from healthy individuals.
Haplotype analysis with highly polymorphic markers was
erformed in these families to investigate whether an
945fs/105 mutation was likely to have arisen from a com-
on ancestor (founder effect). We found that a unique
aplotype, MyBPC3-CA (286) — D11S1784 (144) — D11S1326
247), was linked to the R945fs/105 mutation in all 5 fami-
ies, indicating that a common founder of the mutation was
ikely in these families.
linical manifestation
linical evaluation was performed and all 6 subjects with an
945fs/105 mutation were found to be phenotype-positive.
he clinical characteristics of these six patients at presenta-
ion are summarized in Tables 1 and 2. At initial evaluation,
hree of them (Fig. 1: H108, H180, and H053-III-3) were diag-
osed as having HCM with normal LV systolic function. The
ther two patients (Fig. 1: H053-III-4 and H085) already had
-HCM. The remaining one patient (D025) was diagnosed as
aving DCM because of LV enlargement and reduced LV sys-
olic function in the absence of increased wall thickness in
ny LV segment. H108 was diagnosed at the age of 78 years
ecause of ECG abnormality. She did not present LV out-
ow tract obstruction at initial evaluation in our hospital
fter commencement of treatment with a beta blocker and
isopyramide for LV outﬂow tract gradient of 138mmHg by a
revious physician. H180 was referred for chest pain at the
ge of 59 years and had a classic form of HCM. The proband
f family H053, individual III-3, was seen due to abnormal
CG without any cardiac symptoms at 55 years of age. She
ad asymmetric LV hypertrophy. Her brother, H053-III-4, who
ad symptoms of heart failure (New York Heart Association
II), was diagnosed as having D-HCM at the age of 48 years.
n echocardiographic study showed mildly increased wall
hickness (MLVWT= 15mm) with diffuse hypokinesis of LV
all motion. The global EF was 41%. H085 complained of
hortness of breath and had a LV enlargement with moder-
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tely reduced LV systolic function. She was referred to our
ospital for conﬁrmation of diagnosis of DCM and symptom
anagement. However, detailed observation of the mor-
hology assessed by echocardiography showed that she had a
hickened LV wall in some segments with MLVWT of 15mm. In
ddition, we were able to obtain clinical information on her
ounger sister (Fig. 1: H085-III-3), who had been diagnosed
t another hospital as having classic HCM with asymmetric LV
ypertrophy and normal LV systolic function. Therefore, we
iagnosed the proband of family H085, individual III-2, as
aving D-HCM. D025 was admitted for treatment of heart
ailure at the age of 62 years. Echocardiography showed
V enlargement and moderately reduced LV systolic func-
ion without signiﬁcantly increased LV wall thickness in any
egment (MLVWT= 11mm). Myocardial biopsy showed no sig-
iﬁcant myocardial disarray. We diagnosed him clinically as
aving DCM because there was no previous medical record
nywhere and his relatives were not available for investiga-
ion.
Regarding a family history of sudden death, there were
ve relatives from three families (Fig. 1: families H053,
085, and H108) who died suddenly. One individual died at
2 years of age and the other four individuals died after 40
ears of age.
linical course
able 3 shows the clinical course of six patients with the
utation (R945fs/105). The follow-up period after the ﬁrst
linical evaluation was 7.6± 6.6 (range 1.3—18.0) years.
hree patients with normal LV systolic function at ini-
ial evaluation (H108, H180, and H053-III-3) retained sinus
hythm without detection of paroxysmal atrial ﬁbrillation
AF) and were not hospitalized for treatment of any cardiac
ymptoms. Echocardiography showed preserved LV systolic
unction at the last follow-up in these three patients.
n the other hand, all three patients with reduced LV
ystolic function (H053-III-4, H085, and D025), who were
reated for heart failure and/or arrhythmias with diuret-
cs (n = 3), angiotensin-converting enzyme inhibitors (n = 3),
eta blockers (n = 2), and amiodarone (n = 2), had paroxys-
al or chronic atrial ﬁbrillation at the last follow-up. Two
atients were admitted for treatment of heart failure. Fur-
hermore, two patients (H053-III-4 and D025) received an
mplantable cardioverter deﬁbrillator (ICD) for sustained
entricular tachycardia with instability in circulation. One
atient (H053-III-4) died of heart failure at the age of 62
ears after a 12-year follow-up from the initial diagnosis of
end-stage’ HCM.
iscussion
o date, more than 200 different mutations in different
arcomere genes have been reported in HCM and DCM
atients [5—9,20—22]. Cardiac MyBPC is one of the sarcom-
re proteins, and mutations in the MyBPC gene have been
ssociated with delayed expression of HCM and a favorable
rognosis [10—15]. However, we herein presented differ-
nt clinical proﬁles of MyBPC gene mutation associated with
V systolic dysfunction including D-HCM and clinically diag-
osed DCM.
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linical manifestation
CM is a heterogeneous myocardial disorder with a broad
pectrum of clinical presentations and morphologic features
3,4,23—25]. Although LV systolic function is supernormal
r preserved in most cases of HCM, progression to systolic
mpairment (this subtype is so-called D-HCM) occurs in about
—10% of patients when they are followed for a long time
26—29]. In the present study, half of the patients (three of
he six patients with R945fs/105 mutation) showed LV sys-
olic dysfunction at the time of diagnosis of cardiomyopathy.
wo of these three patients were diagnosed as having D-
CM based on unexplained LVH, i.e., MLVWT ≥15mm and
roven familial HCM with at least one relative who had
n unequivocal diagnosis. The other patient (D025) was
iagnosed clinically as having DCM because there was no
ocumentation of current or previous signiﬁcantly increased
V wall thickness. There was also no relative who had diag-
osis of HCM, although it was possible that the patient might
ave had LV hypertrophy sufﬁcient for diagnosis of HCM pre-
iously.
In the present study, themean age of patients at diagnosis
as 61± 10 years (range, 48—78 years). Onset of the disease
eems to be late in life, although two patients with D-HCM
robably had greater LV wall hypertrophy with normal LV
ystolic function in the early phase. Our data are in accor-
ance with previously reported data for MyBPC mutations
12,14,30—33].
Regarding a family history of sudden death, there were
ve relatives who died suddenly in this study. It is notable
hat the majority of sudden deaths occurred in subjects
ore than 40 years of age (80%; 4 of the 5 individuals).
lthough sudden death in HCM patients occurs most com-
only in children and young adults, it needs to be recognized
hat the risk of sudden death extends across a wide age range
hrough mid-life and beyond [34]. These ﬁndings indicate
hat even middle-aged or older relatives of patients should
e evaluated for family screening strategies.
linical course and prognosis
uring follow-up (7.6± 6.6 years), three patients with nor-
al LV systolic function were clinically stable without
ny cardiovascular events. On the other hand, all three
atients with reduced LV systolic function at presentation
ere hospitalized for treatment of heart failure and/or
CD implantation for sustained ventricular tachycardia. One
atient died of heart failure at the age of 62 years. It is likely
hat a signiﬁcant subset of the patients with this mutation
ill suffer from HCM-related cardiovascular events (heart
ailure and arrhythmias) later in life. Although the clinical
ourse in patients with this mutation is not malignant from
he view point of survival of the mutations, careful man-
gement is needed, particularly in middle-aged and older
atients.enotype/phenotype relations
n R945fs/105 mutation in the MyBPC gene is predicted to
esult in a truncation of the protein, including loss of titin-
inding sites. This mutation was reported previously as a
A
T
eN. Hitomi et al.
ause of HCM without LV systolic dysfunction [35]. Although
his particular mutation has not been associated with LV sys-
olic impairment, several mutations in the MyBPC gene have
een shown to be responsible for HCM with LV systolic dys-
unction and dilatation or DCM (missense mutation: R820Q,
onsense mutation: Q1012X, and frameshift deletion muta-
ion: V593fs, we altered the name V592fs/8) [16,30,36]. In
he case of R820Q mutation in the MyBPC gene, one elderly
atient was reported to be diagnosed as having DCM before
enetic identiﬁcation, similar to a case presented in this
aper, although the other patients with R820Q mutation
ere diagnosed as having HCM [30]. We speculate that our
CM patient (D025) might suffer from D-HCM because the
ther patients carrying the same mutation in this study were
iagnosed as having HCM. Also, there was no previous report
hat mutations in the MyBPC gene were related only to DCM
atients. In some cases, it is difﬁcult to clinically distin-
uish DCM from D-HCM although in patients with D-HCM a
ypertrophied LV wall often remains in some segments even
egression of LVH is observed in the process of LV remodeling.
hese ﬁndings indicate that patients with clinical diagnosis
f DCM may be actually D-HCM from the etiological point of
iew.
Progression from HCM to D-HCM has also been well
emonstrated in patients with cardiac troponin I or tro-
onin T mutations [37,38]. Compared to the phenotypes in
atients caused by these mutations, the age group devel-
ping D-HCM seemed to be older in patients with the
945fs/105 mutation in the MyBPC gene. The differences in
ge for developing D-HCM may be explained by the different
utations or different genes.
imitations
n the present study, not all of the patients with this muta-
ion had LV systolic dysfunction despite the fact that they all
ad identical mutations. These results suggest the involve-
ent of other genetic and/or environmental factors and
nderscore the genetic/phenotypic heterogeneity of HCM.
urther investigations are needed to clarify these modifying
actors.
onclusions
n R945fs/105 mutation in the MyBPC gene was identiﬁed in
of 176 probands with HCM and in 1 of 54 DCM probands.
mong the total of six patients with the mutation, three
atients showed LV systolic dysfunction with cardiac events
f heart failure and arrhythmias: two patients had D-HCM
nd one patient was diagnosed clinically as having DCM. The
atients with this mutation may develop LV systolic dysfunc-
ion and suffer from cardiovascular events through mid-life
nd beyond.cknowledgment
he study was supported by a grant from St Luke’s Life Sci-
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